Nelipepimut-S

DRACPC ID  DRACPC0065

Active Ingredients   Nelipepimut-S

Description  A cancer vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (human epidermal growth factor receptor 2; ErbB2) nonapeptide derived from the extracellular domain of the HER2 protein, with potential immunomodulating and antineoplastic activities. Upon intradermal injection, nelipepimut-S may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cells. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types and plays a key role in tumorigenesis.

Synonyms  E75 Peptide; NeuVax; Human Receptor Tyrosine-Protein Kinase erbB-2 (Proto-Oncogene Neu, Tyrosine Kinase- type Cell Surface Receptor HER2, CD340)-(347-355)-Peptide; L-Leucine, L-lysyl-L-isoleucyl-L-phenylalanylglycyl-L-seryl-L-leucyl-L-alanyl-L- phenylalanyl-; Nelipepimut S; Nelipepimut-S

Type  Biotech

Disease  Prostate cancer, Breast cancer

Classification

  

Peptide and derivative Vaccine 

Structure Information


Molecular Formula  C50H78N10O11

Molecular Weight  995.2

Active Sequence  KIFGSLAFL

Sequence Length  9

Modification  None

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid

InChI  InChI=1S/C50H78N10O11/c1-8-31(6)42(60-44(64)35(52)21-15-16-22-51)49(69)58-37(25-33-17-11-9-12-18-33)45(65)53-27-41(62)55-40(28-61)48(68)57-36(23-29(2)3)46(66)54-32(7)43(63)56-38(26-34-19-13-10-14-20-34)47(67)59-39(50(70)71)24-30(4)5/h9-14,17-20,29-32,35-40,42,61H,8,15-16,21-28,51-52H2,1-7H3,(H,53,65)(H,54,66)(H,55,62)(H,56,63)(H,57,68)(H,58,69)(H,59,67)(H,60,64)(H,70,71)/t31-,32-,35-,36-,37-,38-,39-,40-,42-/m0/s1

InChI_Key AHOKKYCUWBLDST-QYULHYBRSA-N

SMILES  CC(C)C[C@@H](C(O)=O)NC([C@@H](NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](CO)NC(CNC([C@@H](NC([C@@H](NC([C@@H](N)CCCCN)=O)[C@@H](C)CC)=O)CC1=CC=CC=C1)=O)=O)=O)=O)=O)CC2=CC=CC=C2)=O

External Codes


PubChem CID  9941306

DrugBank Accession Number  DB06226

NCI Thesaurus Code  C117985  

UNII  7M0A29CD8B   GSRS

CAS  160212-35-1



Drug approval


Drug indication
    Investigated for use/treatment in prostate cancer and breast cancer.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT02636582 VADIS Trial: Phase II Trial of Nelipeimut-S Peptide Vaccine in Women With DCIS of the Breast Breast Ductal Carcinoma In Situ Phase 2 Prevention
NCT02297698 Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients Breast Cancer Phase 2 Prevention
NCT01479244 PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment Breast Cancer With Low to Intermediate HER2 Expression Phase 3 Prevention
NCT01570036 Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence Breast Cancer Phase 2 Prevention

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.